Chardan raised the firm’s price target on uniQure (QURE) to $37 from $31 and keeps a Buy rating on the shares. The firm cites the company announcement that, following a pre-submission meeting with MHRA, uniQure plans to submit a UK MAA for AMT130 in Huntington’s Disease, the analyst tells investors in a research note. MHRA’s openness and flexibility to work with uniQure is validating of the firm’s conviction on the company’s HD program, the firm added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure advances AMT-130 toward UK marketing approval
- Which 3 Stocks Have the Most Upside in U.S. Chess Champion Hikaru’s Portfolio?
- uniQure price target raised to $10 from $9 at Goldman Sachs
- uniQure call volume above normal and directionally bullish
- Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says